Equity Profile

SYRE

Spyre Therapeutics, Inc.

Health CareBiotechnology$9.0B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

-$0.75

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

SYRE Q2-2026 Earnings Preview

Context

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $9 billion, it operates in the health care sector, where advancements in drug development are crucial for addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In Q1-2026, Spyre reported an EPS of -$0.74, which was worse than the expected -$0.66. Despite this, the stock rose 2.72% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another loss this quarter, with an EPS consensus of -$0.75. Investors will be closely watching for any signs of progress in drug development.

Bull Case

If the company can demonstrate significant advancements in its drug pipeline, it could lead to a positive shift in investor sentiment and stock performance.

Bear Case

On the other hand, continued losses without clear pathways to profitability may lead to further declines in stock value.

Key Metrics to Watch

EPS

-$0.75

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug pipeline or upcoming trials?

Investors are eager to know if there are any breakthroughs that could lead to future revenue.

How does management plan to address the ongoing losses?

Understanding the strategy for moving towards profitability is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Spyre to surprise on the upside if there are any positive developments in their drug pipeline.

Supporting Evidence

The company's history of beating EPS estimates 63% of the time suggests that they could outperform expectations.

Options pricing indicates a larger move than historical averages, suggesting that traders are anticipating significant news.

Key Risk

If the company can show any progress in its drug trials, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether the company can show signs of improving its financial health and operational efficiency.

Bull Confirmed If

A reduction in EPS loss to -$0.49 or better would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$1.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.38%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.4% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (0)P/C Ratio: 4.00Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats expectations with an EPS of -$0.49 or better, history suggests the stock could rise around 1.37% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further guidance.

Miss

A miss on EPS, especially if it exceeds -$1.00, could lead to a decline of about 2.20% based on historical patterns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on drug pipeline progress and any upcoming clinical trials.
2Management's strategy for addressing ongoing losses.
3Any new partnerships or collaborations that could enhance growth.
4Comments on market conditions and competitive landscape.
5Details on cash burn and funding strategies moving forward.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

-$0.75

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

SYRE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In Q1-2026, Spyre reported an EPS of -$0.74, which was worse than the expected -$0.66. Despite this, the stock rose 2.72% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another loss this quarter, with an EPS consensus of -$0.75. Investors will be closely watching for any signs of progress in drug development.

Bull Case

If the company can demonstrate significant advancements in its drug pipeline, it could lead to a positive shift in investor sentiment and stock performance.

Bear Case

On the other hand, continued losses without clear pathways to profitability may lead to further declines in stock value.

Key Metrics to Watch

EPS

-$0.75

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug pipeline or upcoming trials?

Investors are eager to know if there are any breakthroughs that could lead to future revenue.

How does management plan to address the ongoing losses?

Understanding the strategy for moving towards profitability is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Spyre to surprise on the upside if there are any positive developments in their drug pipeline.

Supporting Evidence

The company's history of beating EPS estimates 63% of the time suggests that they could outperform expectations.

Options pricing indicates a larger move than historical averages, suggesting that traders are anticipating significant news.

Key Risk

If the company can show any progress in its drug trials, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether the company can show signs of improving its financial health and operational efficiency.

Bull Confirmed If

A reduction in EPS loss to -$0.49 or better would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$1.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.38%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.4% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (0)P/C Ratio: 4.00Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats expectations with an EPS of -$0.49 or better, history suggests the stock could rise around 1.37% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further guidance.

Miss

A miss on EPS, especially if it exceeds -$1.00, could lead to a decline of about 2.20% based on historical patterns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on drug pipeline progress and any upcoming clinical trials.
2Management's strategy for addressing ongoing losses.
3Any new partnerships or collaborations that could enhance growth.
4Comments on market conditions and competitive landscape.
5Details on cash burn and funding strategies moving forward.